Clinical effect of interferon in treatment of genotype B or C chronic hepatitis B patients: A meta-analysis
10.3969/j.issn.1001-5256.2019.06.015
- VernacularTitle:干扰素治疗B、C基因型慢性乙型肝炎临床效果差异的Meta分析
- Author:
Min LI
1
;
Shan SHAN
;
Xiaoning WU
Author Information
1. National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
- Publication Type:Research Article
- Keywords:
hepatitis B, chronic;
genotype;
interferons;
treatment outcome;
Meta-analysis
- From:
Journal of Clinical Hepatology
2019;35(6):1256-1261
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the clinical effect of interferon (IFN) in the treatment of genotype B or C chronic hepatitis B (CHB) patients. MethodsPubMed, Web of Science, The Cochrane Library, CNKI, Wanfang Data, and VIP were searched for articles on IFN in the treatment of genotype B or C CHB patients published up to November, 2018. Two researchers performed screening, data extraction, and quality assessment of the articles independently, and then a meta-analysis was performed. ResultsA total of 20 articles were included. The results of the meta-analysis showed that compared with the genotype C CHB patients, the genotype B CHB patients had significantly higher HBV DNA clearance rate (odds ratio ［OR］=2.95, 95% confidence interval ［CI］: 2.22-3.91,P＜005), HBeAg clearance rate (OR=3.16, 95%CI: 2.38-4.20,P＜005), HBeAg seroconversion rate (OR=1.83, 95%CI: 1.44-2.33，P＜005), HBsAg clearance rate (OR=2.59, 95%CI: 1.05-6.38，P＜005), and alanine aminotransferase normalization rate (OR=2.31, 95%CI: 1.69-316，P＜005). The subgroup analysis showed that the clinical effect of IFN in genotype B or C CHB patients was not affected by the type of IFN. ConclusionThe antiviral effect of IFNs is affected by HBV genotype, and the patients with genotype B CHB have a better antiviral outcome than those with genotype C CHB. Therefore, HBV genotype is an important factor for predicting the clinical effect of IFN therapy.
